Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction
Javier F. Castroagudín, Esther Molina, Rafael Romero, Esteban Otero, Santiago Tomé, Evaristo Varo – 24 November 2009 – Chronic renal dysfunction is a frequent and severe complication in solid‐organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and sirolimus), can improve renal function in these patients, but available data about the efficacy and safety of everolimus in liver transplant recipients are scarce.